This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ, TAXUS-IV Investigators.Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. Journal of the American College of Cardiology 48: 253-261, No. 2, 18 Jul 2006
Elezi S, Dibra A, Folkerts U, Mehilli J, Heigl S, Schömig A, Kastrati A.Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease. Journal of the American College of Cardiology 48: 262-267, No. 2, 18 Jul 2006
Vaitkus PT.Common sense, dollars and cents, and drug-eluting stents. Journal of the American College of Cardiology 48: 268-269, No. 2, 18 Jul 2006
Rights and permissions
About this article
Cite this article
Drug-eluting stents offer downstream savings. Pharmacoecon. Outcomes News 510, 7 (2006). https://doi.org/10.2165/00151234-200605100-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605100-00017